Inolimomab Biosimilar – Anti-IL2RA mAb – Research Grade

Introduction to Inolimomab Biosimilar – Anti-IL2RA mAb

Inolimomab Biosimilar, also known as Anti-IL2RA mAb, is a research grade monoclonal antibody (mAb) that targets the IL-2 receptor alpha chain (IL2RA). This antibody is a biosimilar of the original Inolimomab, which was approved for clinical use in Europe in 1999 for the treatment of graft-versus-host disease (GVHD). Inolimomab Biosimilar is currently being developed for the treatment of various autoimmune and inflammatory diseases.

Structure of Inolimomab Biosimilar

Inolimomab Biosimilar is a recombinant humanized IgG1 monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. It has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL) and one variable domain (VL). The variable domains of both the heavy and light chains are responsible for binding to the IL2RA receptor.

Activity of Inolimomab Biosimilar

Inolimomab Biosimilar binds specifically to the IL2RA receptor, which is found on the surface of activated T cells, B cells, and natural killer (NK) cells. The binding of Inolimomab Biosimilar to the IL2RA receptor blocks the binding of IL-2, a pro-inflammatory cytokine, to its receptor. This prevents the activation and proliferation of T cells, which play a key role in autoimmune and inflammatory diseases. In addition, Inolimomab Biosimilar also induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against IL2RA-expressing cells, leading to their destruction.

Application of Inolimomab Biosimilar

Inolimomab Biosimilar is currently being studied for the treatment of various autoimmune and inflammatory diseases, including GVHD, multiple sclerosis, and rheumatoid arthritis. In GVHD, Inolimomab Biosimilar is used to prevent the activation and proliferation of donor T cells, which can attack the recipient’s tissues and organs. In multiple sclerosis, Inolimomab Biosimilar is being investigated as a potential therapy to target the activated T cells that attack the myelin sheath in the central nervous system. In rheumatoid arthritis, Inolimomab Biosimilar is being studied to block the activation and proliferation of T cells that contribute to the inflammation and joint damage in this disease.

Inolimomab Biosimilar has also shown potential in the treatment of other autoimmune and inflammatory diseases, such as psoriasis, Crohn’s disease, and lupus. The use of Inolimomab Biosimilar in these diseases is based on the fact that IL2RA is overexpressed on the surface of activated T cells in these conditions.

Conclusion

Inolimomab Biosimilar, also known as Anti-IL2RA mAb, is a research grade monoclonal antibody that targets the IL-2 receptor alpha chain. It is a biosimilar of the original Inolimomab and is being developed for the treatment of various autoimmune and inflammatory diseases. Its mechanism of action involves blocking the binding of IL-2 to its receptor and inducing cell death of IL2RA-expressing cells. Inolimomab Biosimilar has shown promising results in clinical trials and has the potential to provide a safe and effective treatment option for patients with autoimmune and inflammatory diseases.